Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for Derica W. Rice
+0.71 (0.88%)
After Hours: 80.50 -0.57 (-0.70%)
Feb 22, 6:55PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 80.33 - 81.21
52 week 64.18 - 83.79
Open 80.42
Vol / Avg. 0.00/4.40M
Mkt cap 89.46B
P/E 31.43
Div/yield 0.52/2.57
EPS 2.58
Shares 1.10B
Beta 0.29
Inst. own 77%
Jan 31, 2017
Q4 2016 Eli Lilly and Co Earnings Release
Jan 31, 2017
Q4 2016 Eli Lilly and Co Earnings Call
Jan 10, 2017
Eli Lilly and Co at JPMorgan Healthcare Conference
Dec 15, 2016
Eli Lilly and Co 2017 Financial Guidance Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 13.40% 12.90%
Operating margin 15.21% 16.30%
EBITD margin - 18.24%
Return on average assets - -
Return on average equity - -
Employees 41,275 -
CDP Score - 89 C


Lilly Corporate Ctr, Drop Code 1112
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
David A. Ricks Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 51
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 56
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 62
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 48
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 53
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 50
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 49
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 51
Bio & Compensation  - Reuters